TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29248173
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C (0.4 mg/ml for 2 minutes)
Study: 29092079
Drug: Intranasal benzhydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal benzhydrocodone API (13.34 mg)
Study: 29092079
Drug: Intranasal hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hydrocodone bitartrate API (15.0 mg)
Study: 26365330
Drug: 15‐mg zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐mg zinc sulfate daily from the 16th week of gestation until delivery
Study: 26365330
Drug: 15‐mg zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐mg zinc sulfate
Study: 24210923
Drug: Gastrostomy tube
Normalized name: gastrostomy tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrostomy tube (G-tube) feeding
Study: 24210923
Drug: Oral only
Normalized name: TABLET, ORAL ONLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral only feeding
Study: 22658359
Drug: Itraconazole in
Normalized name: itraconazole Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole in addition to DMARD therapy
Study: 22658359
Drug: Standard DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DMARD therapy plus placebo
Study: 18681789
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg clomiphene citrate plus placebo (n = 209)
Study: 18681789
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g extended-release metformin plus placebo (n = 208)
Study: 18681789
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and clomiphene (n = 209)
Study: 18681789
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR (2 g/day)
Study: 8934149
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg nicotine gum)
Study: 25275724
Drug: MVA E2
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA E2 therapeutic vaccine (10^7 virus particles injected directly into uterus, urethra, vulva, or anus)
Study: 19363022
Drug: Dexamethasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (100 mg intramuscular injections at baseline and 6 weeks)
Study: 11927515
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEEs) 0.625 mg
Study: 11927515
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CEEs and simvastatin
Study: 7500130
Drug: Daily 2‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2‐h manual practice sessions for 5 days
Study: 7500130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group 1: Daily TMS mapping without piano practice
Study: 2613427
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (very low calorie diet + behavior therapy)
Study: 773495
Drug: Dipyridamole and
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole and aspirin (given by mouth from the evening before operation and for seven days after operation)
Study: 31842127
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid treatment
Study: 31842127
Drug: Non-acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-acetylsalicylic acid treatment
Study: 26769332
Drug: INCB039110 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB039110 100 mg once daily
Study: 26769332
Drug: INCB039110 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB039110 200 mg once daily
Study: 26769332
Drug: INCB039110 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB039110 200 mg twice daily
Study: 26769332
Drug: INCB039110 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB039110 600 mg once daily
Study: 25171502
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg (TAM) + Solifenacin 5 mg (SOL)
Study: 25171502
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg (TAM)
Study: 17618427
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid 200 mg t.i.d. for 3 days
Study: 15908834
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) at doses of 0.45 mg/h, 0.9 mg/h, and 1.8 mg/h
Study: 10469092
Drug: Liposome-encapsulated caffeine-based
Normalized name: caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposome-encapsulated caffeine-based cream (higher concentration)
Study: 10469092
Drug: Liposome-encapsulated caffeine-based
Normalized name: caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposome-encapsulated caffeine-based cream (lower concentration)
Study: 2153719
Drug: Topical nedocromil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nedocromil sodium
Study: 7018644
Drug: Hydroxyzine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 0.5 mg/kg (n = 43)
Study: 7018644
Drug: Promethazine 0.5
Normalized name: PROMETHAZINE 0.5MG/ML/NACL INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 0.5 mg/kg (n = 40)
Study: 7018644
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg/kg (n = 378)
Study: 31727664
Drug: Rotarix (third
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix (third dose)
Study: 22429586
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week (eow) as continuous treatment
Study: 22429586
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week (eow) after retreatment
Study: 22429586
Drug: Adalimumab continuous
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab continuous treatment
Study: 22016976
Drug: Method for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method for calming the liver and suppressing Yang (Traditional Chinese Medicine)
Study: 22016976
Drug: Thiamazole tablets
Normalized name: thiamazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamazole tablets
Study: 9177609
Drug: UVB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatment (15 patients)
Study: 9177609
Drug: PUVA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA treatment (11 patients)
Study: 22722512
Drug: MK-0657 monotherapy
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0657 monotherapy (4-8 mg/d)
Study: 12113286
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg per day
Study: 10892417
Drug: Oxytocin antagonists
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin antagonists
Study: 8750221
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) insulin infusion at 2 mU/kg‐1 min‐1
Study: 8750221
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) insulin infusion at 1 mU/kg‐1 min‐1
Study: 6358126
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose nimodipine therapy
Study: 27128606
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (SD) of GSK2018682 up to 24 mg
Study: 27128606
Drug: Repeat dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose (RD) of GSK2018682 up to 6 mg/day for 28 days
Study: 27128606
Drug: GSK2018682 RD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GSK2018682 RD of 6 mg
Study: 17823517
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied twice daily for 7 days
Study: 17823517
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 7 days
Study: 1534729
Drug: Lactase treatment
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase treatment (9900 FCC units, 3 chewable tablets)
Study: 1534729
Drug: Lactase treatment
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase treatment
Study: 30077803
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy (DBT) skills group
Study: 24812071
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention including monthly breastfeeding learning sessions, weekly text and voice messages, and participant-generated songs and dramas.
Study: 22250885
Drug: Self‐administered computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered computer therapy targeting whole word production with error reduction strategies
Study: 19281013
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (acupuncture, obturation, needle-knife)
Study: 17229323
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g alcohol (one drink)
Study: 17229323
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol (two drinks)
Study: 16333887
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy with adjuvant propranolol (40 mg tds)
Study: 16333887
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy only
Study: 16333887
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy with adjuvant propranolol
Study: 12223437
Drug: High-fiber group
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber group (13.5 g/day)
Study: 12223437
Drug: Low-fiber group
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber group (2.0 g/day)
Study: 12223437
Drug: Supplemental fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental fiber intake greater than 11.0 g/day
Study: 12223437
Drug: Total fiber
Normalized name: Konsyl CARE TOTAL FIBER Psyllium Fiber 6g Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total fiber intake greater than 30.3 g/day
Study: 9653495
Drug: FU-Plus-LV (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU-Plus-LV (400 mg/m2/day FU + 20 mg/m2/day LV for 5 days)
Study: 9653495
Drug: FU Alone
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU Alone (400 mg/m2/day FU)
Study: 7858400
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate < 6.0 mg.kg‐1.h‐1
Study: 7858400
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion rate > 6.0 mg.kg‐1.h‐1
Study: 31977699
Drug: Microneedling therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling therapy
Study: 31033013
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) in dim light (10 lux)
Study: 31033013
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) in bright light (2000 lux)
Study: 12583942
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg salmeterol twice daily (n=372)
Study: 12583942
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg fluticasone twice daily (n=374)
Study: 12583942
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg salmeterol and 500 microg fluticasone twice daily (n=358)
Study: 1783346
Drug: Gelofalk (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofalk (a combination of smectite, aluminium hydroxide, and magnesium hydroxide)
Study: 1783346
Drug: Aluminium hydroxide
Normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium hydroxide antacid (control)
Study: 7211892
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of medroxyprogesterone (MPG) daily for approximately one month
Study: 26905220
Drug: Routine heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine heart failure treatment (Control)
Study: 26905220
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to BNP-guided therapy
Study: 26905220
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to BNP-guided therapy
Study: 25213052
Drug: Lansoprazole treatment
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole treatment
Study: 19618317
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment for 8 weeks
Study: 17243866
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) (10 microg or 400 IU) plus calcium (1000 mg/day)
Study: 15331942
Drug: Citrate plus
Normalized name: Walgreens Calcium Citrate Plus D3 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate plus low-dose heparin
Study: 11978136
Drug: Systemic corticosteroids
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroids (100 to 200 mg/day in the initial phase)
Study: 11978136
Drug: Cyclosporine (mainly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (mainly as maintenance treatment)
Study: 11978136
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of corticosteroids with cytotoxic drugs (azathioprine, cyclophosphamide, chlorambucil)
Study: 11978136
Drug: Corticosteroids with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids with sulfa drugs (dapsone, clofazimine, minocycline, thalidomide)
Study: 11978136
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of granulocyte-macrophage colony-stimulating factor, intravenous immunoglobulins, plasmapheresis
Study: 11978136
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with modern wound dressings
Study: 11978136
Drug: Systemic antibacterial
Normalized name: Trimethoprim and derivatives, systemic antibacterials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibacterial therapy
Study: 31832638
Drug: Cotrimoxazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole treatment (CTX-T)
Study: 31832638
Drug: No cotrimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cotrimoxazole treatment (CTX-N)
Study: 19535429
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) (8 g oil/d)
Study: 19535429
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (SAF) (8 g oil/d)
Study: 11449087
Drug: Estrogen group
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 2 placebo tablets and 5 ethinyl‐estradiol tablets of 10 microg each)
Study: 11449087
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 7 placebo tablets)
Study: 7839843
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no metallic implant)
Study: 2835245
Drug: Intravenous L-648,051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-648,051 (35, 52.5, and 70 mg/5 min infusion)
Study: 2835245
Drug: Aerosolized L-648,051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized L-648,051 (0.1 to 1.6 mg)
Study: 31511279
Drug: Oligosaccharide-sialic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligosaccharide-sialic acid (OS) preparation
Study: 27687823
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy group (EG) - home‐based progressive strength and aerobic training program for 12 months
Study: 27687823
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group (UCG) - received only oral and written instructions of exercises
Study: 27687823
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy group (EG)
Study: 19165529
Drug: MPH ER
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH ER (10 mg/day to 60 mg/day)
Study: 9229881
Drug: Indomethacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.1 mg/kg bolus followed by continuous infusion 0.1 mg/kg/h
Study: 9229881
Drug: Indomethacin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.2 mg/kg bolus followed by continuous infusion 0.2 mg/kg/h
Study: 9229881
Drug: Indomethacin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.3 mg/kg bolus followed by continuous infusion 0.3 mg/kg/h
Study: 8387576
Drug: Standard-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles
Study: 8387576
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles
Study: 8387576
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1
Study: 2893636
Drug: Ketanserin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (mean daily dose 77 mg)
Study: 2893636
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean daily dose 62 mg)
Study: 28568974
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg mesalazine tablets (3.2 g oral mesalazine, administered as two 1600 mg tablets once daily)
Study: 28568974
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg mesalazine tablets (4 tablets twice daily)
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min with 20% vital capacity
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min with 50% vital capacity
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min with 80% vital capacity
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min with 20% vital capacity
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min with 50% vital capacity
Study: 7241435
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min with 80% vital capacity
Study: 31678536
Drug: Double-targeted DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-targeted DNA vaccine of Vibrio mimicus
Study: 26306418
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy intervention provided by trained pharmacists (stimulus control and sleep restriction) over three pharmacy visits (baseline, 1 and 3 months follow-up)
Study: 19833998
Drug: Abstinence-contingent housing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-contingent housing, vocational training, work, plus cognitive behavioral day treatment
Study: 19833998
Drug: Consecutive weeks
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consecutive weeks of abstinence during treatment
Study: 15658951
Drug: BIBN4096BS 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN4096BS 2.5 mg
Study: 15658951
Drug: BIBN4096BS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN4096BS 10 mg
Study: 15658951
Drug: BIBN4096BS (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN4096BS (2.5 mg and 10 mg)
Study: 2181623
Drug: Chewable antacid
Normalized name: CALCIUM CARBONATE 500 mg ORAL TABLET, CHEWABLE [CALCIUM CARBONATE CHEWABLE ANTACID]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable antacid tablet (30 mmol) four times daily
Study: 7418711
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of hydrochlorothiazide daily
Study: 7418711
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of reserpine daily